Sstr-positive cancer cells were chosen as the therapeutic target of vaccinia VG9/(SST-14)2-HSA, because the anti-tumor effect of (SST-14)2-HSA must be activated through the interaction with sstrs. This evidence concerns the gene ALB and neoplasm.